{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.4","value":"23.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.7","value":"26.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.8","value":"32.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"title":"Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.8","value":"32.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"title":"Day 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.1","value":"33.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Day 71"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.6","value":"45.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"title":"Day 85"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.0","value":"40.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Day 99"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.6","value":"43.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Day 169"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Day 211"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.7","value":"38.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Day 253"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.7","value":"43.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 337"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.79","value":"61.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Day 421"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"Minimum serum post-dose (Ctrough) concentration of avelumab was reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part A: Avelumab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set consists of all participants who received at least 1 dose of avelumab, and provide at least 1 measurable post-dose concentration. Here \"Number analyzed\" signifies those participants who were evaluable at specified timepoints","reportingStatus":"POSTED","timeFrame":"Day 15, 29, 43, 57, 71, 85, 99, 169, 211, 253, 337 and 421","title":"Part A: Minimum Serum Post-dose (Ctrough) Concentration of Aveluamb","type":"SECONDARY","unitOfMeasure":"Micrograms per milliliter"}